NGP cells were chosen among the MYCN-amplified NB cells with the highest in vitro IC50.The continuous in vivo treatment with the SGSS05-NS3 compound significantly reduced the NB in vivo outgrowth without any evidence of toxicity (Fig. 5G-H). The gene discussed is KRAS; the disease is neuroblastoma.